Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 |
| clinicaltrials |
| NCT02112175 | Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM(ARUMM) | completed | Phase 3 | 46 | CelgeneINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment(PO-3887) | terminated | Phase 3 | 9 | Fondazione EMN Italy OnlusOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT02322320 | Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | completed | Phase 3 | 273 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 11, 2020 | clinicaltrials |
| NCT01413178 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 3 | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01146834 | Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma | completed | Phase 3 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00622336 | A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | completed | Phase 3 | 330 | CelgeneINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma(FIRST) | completed | Phase 3 | 1,623 | CelgeneINDUSTRY | 19 | Nov 20, 2019 | clinicaltrials |
| NCT00928486 | A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 25 | CelgeneINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01324947 | Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | completed | Phase 3 | 74 | CelgeneINDUSTRY | 15 | Nov 19, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT02811978 | Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 3 | 81 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00657488 | Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 400 | CelgeneINDUSTRY | 2 | Oct 18, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03792620 | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation(MAXDARA) | unknown | Phase 3 | 20 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | terminated | Phase 3 | 147 | AB ScienceINDUSTRY | 2 | Dec 19, 2018 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038233 | Thalidomide for Multiple Myeloma | completed | Phase 3 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01908621 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | completed | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00232934 | Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients | completed | Phase 3 | 400 | Gruppo Italiano per lo Studio del Mieloma MultiploOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 0 | Apr 10, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | completed | Phase 3 | 97 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | terminated | Phase 3 | 20 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | terminated | Phase 3 | 10 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT00056160 | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 353 | CelgeneINDUSTRY | 2 | Oct 19, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02248428 | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma(CTd) | unknown | Phase 3 | 130 | Jinling Hospital, ChinaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT00097981 | A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 225 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
| NCT01910987 | Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib(OPTIMRETREAT) | completed | Phase 3 | 80 | Janssen-Cilag International NVINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | completed | Phase 3 | 459 | Celgene CorporationINDUSTRY | 22 | Jan 11, 2017 | clinicaltrials |
| NCT02916420 | Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 73 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2021source: clinicaltrials